Beijing Mabworks Biotech is a gene engineering monoclonal antibody company focused on therapeutic antibodies and biosimilars. The company is working on ZMapp, an Ebola treatment developed by San Diego’s MAPP Biopharma. It has two clinical-stage candidates: MIL60, a biosimilar to Genentech’s Avastin, and MIL62, a proposed treatment for chronic lymphocytic leukemia. Founded in 2003, Mabworks completed a $39 million Series B financing. The Series B was led by Shenzhen GTJA Investment Group. GTJA is described in the article as a healthcare-focused investment firm.

Total raised

$39M

Funding rounds

1

Latest round

Series B

Latest activity

Jan 2017